Targeted Degradation of mRNA Decapping Enzyme DcpS by a VHL-Recruiting PROTAC

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• The RNA decapping scavenger protein, DcpS, is a newly identified dependency in acute myeloid leukemia (AML).
• DcpS inhibition or knockdown shows antiproliferative effects in AML cells.
• DcpS is non-essential in normal hematopoietic cells, suggesting a therapeutic window for AML treatment.

Purpose of the Study:

• To explore Proteolysis-Targeting Chimeras (PROTACs) for DcpS modulation in AML.
• To develop a PROTAC-mediated strategy for targeted DcpS degradation.

Main Methods:

• Development and characterization of JCS-1, a novel PROTAC molecule.
• Assessment of JCS-1's efficacy in degrading DcpS in AML cell lines.
• Utilizing a RG3039-based warhead and VHL E3 ligase recruitment.

Main Results:

• JCS-1 effectively degrades DcpS at nanomolar concentrations.
• JCS-1 induces potent, rapid, and sustained DcpS degradation in multiple AML cell lines.
• The PROTAC JCS-1 demonstrates non-covalent binding to DcpS.

Conclusions:

• PROTAC-mediated degradation is a viable strategy for targeting DcpS in AML.
• JCS-1 serves as a valuable chemical biology tool for studying DcpS degradation and RNA processes.
• Targeting DcpS degradation presents an attractive therapeutic approach for AML and other DcpS-dependent disorders.